Good clinical practice, commonly known as GCP, is the international standard that governs how clinical trials are designed, conducted, monitored, recorded, and reported. Established to protect the rights, integrity, and confidentiality of trial participants, good clinical practice ensures that data generated in clinical research is credible, accurate, and ethically obtained. For any organization involved in clinical research, understanding GCP is not optional — it is the foundation on which every study is built.
At FOMAT, all clinical trial activities across our national network of investigator sites are conducted in full compliance with GCP requirements, ensuring that sponsors and CROs receive data that meets the highest regulatory and ethical standards.
What is good clinical practice and why does it matter
Good clinical practice is an international ethical and scientific quality standard developed to bring consistency to clinical trial design and execution across countries. It was finalized in 1996 and became effective in 1997 through the International Conference for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, known as ICH. The resulting guideline, ICH-GCP E6, unified previously fragmented national and regional standards into a single global framework. Compliance with GCP is today a legal obligation in most major regulatory jurisdictions, including the United States, the European Union, and the United Kingdom.
The core purpose of good clinical practice is threefold: protect trial participants, ensure data integrity, and provide a basis for regulatory confidence in clinical trial results. Without GCP, the results of a trial cannot be trusted, and the drugs derived from that research cannot be approved.
The historical events that shaped good clinical practice
The development of GCP did not happen in a vacuum. It is the direct result of a series of ethical failures and public health crises that forced governments and scientific communities to act.
The first major regulatory milestone in the United States was the Food and Drugs Act of 1906, passed in response to dangerous patent medicines freely available to consumers. In 1938, the Federal Food, Drug, and Cosmetic Act required manufacturers to demonstrate drug safety to the FDA before marketing — a foundational shift in how medicines were regulated.
The Nuremberg Code of 1947, developed in the aftermath of unethical human experimentation conducted at Nazi war camps during World War II, established the principle of voluntary informed consent as a non-negotiable requirement in human research. The Declaration of Helsinki, developed by the World Medical Association in 1964, expanded on these principles and remains the ethical framework underlying modern good clinical practice guidelines.
In 1962, severe fetal deformities linked to thalidomide — a drug taken by pregnant women in over 20 countries — led to the Kefauver-Harris Amendments, requiring the FDA to evaluate new drugs for both safety and efficacy, not safety alone. The Belmont Report of 1979 further codified the ethical principles of respect for persons, beneficence, and justice that continue to guide clinical research today. The Mayo Clinic notes that protecting participant welfare is central to how clinical trials are conducted and reviewed.
The 13 core principles of ICH good clinical practice
The ICH-GCP guidelines are organized around 13 core principles that together define what ethical, scientifically sound clinical research looks like. In summary, they require that:
Clinical trials must follow ethical principles rooted in the Declaration of Helsinki. The anticipated benefits of a trial must justify its risks. Participant rights, safety, and wellbeing take priority over scientific and commercial interests. Investigational products must be supported by adequate preclinical and clinical data. Trials must follow clear, detailed, IRB or IEC-approved protocols. All medical decisions must be made by qualified physicians. Every person involved in a trial must be qualified by education, training, and experience. Informed consent must be freely obtained from every participant. All trial data must be recorded, handled, and stored to allow accurate reporting and verification. Participant confidentiality must be maintained throughout. Investigational products must be manufactured and handled according to Good Manufacturing Practice. Quality assurance systems must be implemented at every stage of the trial.
These principles collectively ensure that good clinical practice is not a checklist but a culture — one that prioritizes participant protection and scientific rigor at every level of a study.
Who is responsible for good clinical practice in a clinical trial
GCP responsibilities are shared across multiple parties. Sponsors are responsible for the overall design, management, and funding of the trial. Contract research organizations like FOMAT carry out operational responsibilities delegated by the sponsor, including site management, patient recruitment, and data collection. Investigators at each site are responsible for the direct conduct of the trial and the medical care of participants. Institutional Review Boards or Independent Ethics Committees provide independent oversight and must approve all trial protocols before a study begins.
Each party operates under clearly defined GCP obligations, and any failure at any level can compromise the validity of the entire trial. FOMAT’s quality and compliance framework is built to support sponsors and CROs in meeting these obligations at every site in our network.
Good clinical practice and the future of clinical research
As clinical trials grow in complexity — expanding into decentralized models, real world evidence studies, and adaptive trial designs — the principles of good clinical practice remain the constant. Regulatory agencies including the FDA continue to update GCP guidance to reflect new trial methodologies, but the underlying ethical commitments do not change.
For sponsors and CROs evaluating research partners, GCP compliance is not just a regulatory requirement — it is a measure of organizational competence and ethical commitment. FOMAT’s Phase I through Phase IV capabilities are designed with GCP compliance embedded at every stage, from protocol development through final data reporting.
Good clinical practice is what makes clinical research trustworthy. And trustworthy research is what makes better medicines possible.